Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, speaks to us about the different therapies being developed for the treatment of breast cancer. Dr Burris touches upon personalized medicine and how it is helping to determine the best course of treatment, before discussing new data from trials including TAILORx (NCT00310180) and PERSEPHONE (ISRCTN52968807). Dr Burris mentions the limitations currently posed by these new therapies, before concluding his interview by briefly mentioning the use of pembrolizumab and combination therapy in the treatment of non-small cell lung cancer. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Breast cancer: new advances in personalized medicine and therapeutics
